UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2225-5
Program Prior Authorization/Medical Necessity
Medication Mycapssa™ (octreotide)
P&T Approval Date 12/2020, 12/2021, 12/2022, 12/2023, 1/2025
Effective Date 4/1/2025
1. Background:
Mycapssa (octreotide) is a somatostatin analog indicated for long-term maintenance treatment
in acromegaly patients who have responded to and tolerated treatment with octreotide or
lanreotide. Somatostatin analogs are recommended in patients who are not candidates or who
have had an inadequate response to surgery.
2. Coverage Criteria a:
A. Acromegaly
1. Initial Authorization
a. Mycapssa will be approved based on one of the following criteria:
(1) All of the following:
(a) Diagnosis of acromegaly by one of the following:
i. Serum GH level > 1 ng/mL after a 2-hour oral glucose tolerance test
(OGTT) at time of diagnosis
ii. Elevated serum IGF-1 levels (above the age and gender adjusted normal
range as provided by the physician’s lab) at time of diagnosis
-AND-
(b) One of the following:
i. Inadequate response to one of the following:
• Surgical resection
• Pituitary irradiation
• Bromocriptine mesylate at maximally tolerated dose
-OR-
ii. Not a candidate for any of the following:
• Surgical resection
• Pituitary irradiation
• Bromocriptine mesylate at maximally tolerated dose
© 2025 UnitedHealthcare Services, Inc.
1
-AND-
(c) Patient has responded to and tolerated treatment with one of the following
somatostatin analogs:
i. Sandostatin (octreotide) or Sandostatin LAR
ii. Somatuline Depot (lanreotide)
-AND-
(d) The provider has submitted clinical justification why the patient is unable to
be maintained on current octreotide or lanreotide therapy
-OR-
(2) Patient is currently on Mycapssa therapy for acromegaly
Authorization will be issued for 12 months.
2. Reauthorization
a. Mycapssa will be approved based on the following criteria:
(1) Documentation of positive clinical response to Mycapssa therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Mycapssa [package insert]. Scotland, UK: MW Encap Ltd.; August 2024.
2. Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an endocrine society clinical
practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933-3951.
doi:10.1210/jc.2014-2700
Program Prior Authorization/Medical Necessity - Mycapssa® (octreotide)
Change Control
12/2020 New program
12/2021 Annual review with no change to clinical criteria.
© 2025 UnitedHealthcare Services, Inc.
2
12/2022 Annual review with no change to clinical criteria. Updated references.
12/2023 Annual review with no change to clinical criteria.
12/2024 Annual review. Updated wording of criteria without change in clinical
intent. Updated references.
© 2025 UnitedHealthcare Services, Inc.
3